SecBot SecBot
8-K ·Filed Aug 25, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001193125-26-364210
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

This is a routine executive appointment with no immediate financial read-through. Monitor for upcoming clinical data readouts or pipeline updates that may be influenced by Dr. Patni's leadership.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$41.30
T+0 close · Aug 25, 2026 · via day close
Latest settled
−6.90%
T+20 · $38.45 · next T+60 tomorrow
Vs SPY
−7.88%
α at T+20
Latest observation
+20.92%
T+57 · FF3 residual α
  1. T+0 · Aug 25 $41.30entry
  2. T+1 · 3mo ago −2.54%α −2.56% · $40.25
  3. T+5 · 3mo ago −8.77%α −8.23% · $37.68
  4. T+20 · 8w ago −6.90%α −7.88% · $38.45
  5. T+58 · todayOpen
  6. T+60 · tomorrow Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni brings over 25 years of biopharmaceutical experience and a track record of 10 regulatory approvals, which is a positive signal for the company's clinical-stage pipeline execution. This is a routine executive hire for a clinical-stage biotech and does not include any financial data or guidance changes.

Key Facts

  • Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026.
  • Dr. Patni has over 25 years of experience and has contributed to 10 regulatory agency approvals or label expansions.
  • He most recently served as CEO of Judo Bio and previously as CMO at Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals.
  • The filing contains no financial data, guidance, or material business updates.

Financial Impact

No financial impact disclosed in the filing.

Risk Factors

  • No financial data or guidance was provided in the filing.
  • The appointment does not change the company's near-term cash runway or clinical timelines.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-364210
Document: 0001193125-26-364210-index.html0001193125-26-364210
Document: 0001193125-26-364210.txt0001193125-26-364210

US Market Status

Market Closed · Opens Wed (12h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026